Karim Alavi to Rectal Neoplasms
This is a "connection" page, showing publications Karim Alavi has written about Rectal Neoplasms.
Connection Strength
5.919
-
Maykel JA, Hahn SJ, Beauharnais CC, Meyer DC, Hill SS, Sturrock PR, Davids JS, Alavi K. Oncologic Outcomes After Transanal Total Mesorectal Excision for Rectal Cancer. Dis Colon Rectum. 2022 06 01; 65(6):827-836.
Score: 0.713
-
Springer JE, Beauharnais C, Chicarilli D, Coderre D, Crawford A, Baima JA, McIntosh LJ, Davids JS, Sturrock PR, Maykel JA, Alavi K. S184: preoperative sarcopenia is associated with worse short-term outcomes following transanal total mesorectal excision (TaTME) for rectal cancer. Surg Endosc. 2022 07; 36(7):5408-5415.
Score: 0.697
-
Hill SS, Chung SK, Meyer DC, Crawford AS, Sturrock PR, Harnsberger CR, Davids JS, Maykel JA, Alavi K. Impact of Preoperative Care for Rectal Adenocarcinoma on Pathologic Specimen Quality and Postoperative Morbidity: A NSQIP Analysis. J Am Coll Surg. 2020 01; 230(1):17-25.
Score: 0.599
-
Alavi K. Expert Commentary on the Diagnosis and Treatment of Rectal GI Tumors. Dis Colon Rectum. 2019 05; 62(5):540-541.
Score: 0.579
-
Maykel JA, Phatak UR, Suwanabol PA, Schlussel AT, Davids JS, Sturrock PR, Alavi K. Initiation of a Transanal Total Mesorectal Excision Program at an Academic Training Program: Evaluating Patient Safety and Quality Outcomes. Dis Colon Rectum. 2017 Dec; 60(12):1267-1272.
Score: 0.525
-
Chan SY, Suwanabol PA, Damle RN, Davids JS, Sturrock PR, Sweeney WB, Maykel JA, Alavi K. Characterizing Short-Term Outcomes Following Surgery for Rectal Cancer: the Role of Race and Insurance Status. J Gastrointest Surg. 2016 11; 20(11):1891-1898.
Score: 0.481
-
Brady JT, Wright JP, Davids JS, Kelley SR, Alavi K, Stein SL, Monson JRT, Xu Z. The impact of nonoperative management of rectal cancer on colon and rectal surgery residents in the United States. Colorectal Dis. 2025 May; 27(5):e70125.
Score: 0.219
-
Donovan KF, Lee KC, Ricardo A, Berger N, Bonaccorso A, Alavi K, Zaghiyan K, Pigazzi A, Sands D, DeBeche-Adams T, Chadi SA, McLemore EC, Marks JH, Maykel JA, Shawki SF, Steele SR, Albert M, Whiteford MH, Cheng FY, Wexner SD, Sylla P. Functional Outcomes After Transanal Total Mesorectal Excision (taTME) for Rectal Cancer: Results From the Phase II North American Multicenter Prospective Observational Trial. Ann Surg. 2024 Sep 01; 280(3):363-373.
Score: 0.206
-
Zewde MG, Peyser DK, Yu AT, Bonaccorso A, Moshier E, Alavi K, Goldstone R, Marks JH, Maykel JA, McLemore EC, Sands D, Steele SR, Wexner SD, Whiteford M, Sylla P. Oncologic outcomes following transanal total mesorectal excision: the United States experience. Surg Endosc. 2024 Jul; 38(7):3703-3715.
Score: 0.206
-
Sylla P, Sands D, Ricardo A, Bonaccorso A, Polydorides A, Berho M, Marks J, Maykel J, Alavi K, Zaghiyan K, Whiteford M, Mclemore E, Chadi S, Shawki SF, Steele S, Pigazzi A, Albert M, DeBeche-Adams T, Moshier E, Wexner SD. Multicenter phase II trial of transanal total mesorectal excision for rectal cancer: preliminary results. Surg Endosc. 2023 12; 37(12):9483-9508.
Score: 0.196
-
Geisler BP, Cao KN, Ryschon AM, Alavi K, Komen N, Pietzsch JB. Cost associated with diverting ostomy after rectal cancer surgery: a transnational analysis. Surg Endosc. 2023 10; 37(10):7759-7766.
Score: 0.195
-
Sylla P, Berho M, Sands D, Ricardo A, Bonaccorso A, Moshier E, Hain E, Letchinger R, Marks J, Whiteford M, Mclemore E, Maykel J, Alavi K, Zaghiyan K, Chadi S, Shawki SF, Steele S, Pigazzi A, Albert M, DeBeche-Adams T, Polydorides A, Wexner S. Discordance in Total Mesorectal Excision Specimen Grading in a Prospective Phase 2 Multicenter Rectal Cancer Trial: Are We Overestimating the Quality of Our Resections? Ann Surg. 2023 09 01; 278(3):452-463.
Score: 0.194
-
Beauharnais CC, Aulet T, Rodriguez-Silva J, Konen J, Sturrock PR, Alavi K, Maykel JA, Davids JS. Assessing the Quality of Online Health Information and Trend Data for Colorectal Malignancies. J Surg Res. 2023 03; 283:923-928.
Score: 0.186
-
Caminsky NG, Moon J, Morin N, Alavi K, Auer RC, Bordeianou LG, Chadi SA, Drolet S, Ghuman A, Liberman AS, MacLean T, Paquette IM, Park J, Patel S, Steele SR, Sylla P, Wexner SD, Vasilevsky CA, Rajabiyazdi F, Boutros M. Patient and surgeon preferences for early ileostomy closure following restorative proctectomy for rectal cancer: why aren't we doing it? Surg Endosc. 2023 01; 37(1):669-682.
Score: 0.184
-
Alavi K. Systematic Reviews and Meta-analytic Methods: Not All Are Created Equal. Dis Colon Rectum. 2018 11; 61(11):1241-1242.
Score: 0.140
-
Hawkins AT, Albutt K, Wise PE, Alavi K, Sudan R, Kaiser AM, Bordeianou L. Abdominoperineal Resection for Rectal Cancer in the Twenty-First Century: Indications, Techniques, and Outcomes. J Gastrointest Surg. 2018 08; 22(8):1477-1487.
Score: 0.135
-
Glasgow SC, Morris AM, Baxter NN, Fleshman JW, Alavi KS, Luchtefeld MA, Monson JR, Chang GJ, Temple LK. Development of The American Society of Colon and Rectal Surgeons' Rectal Cancer Surgery Checklist. Dis Colon Rectum. 2016 Jul; 59(7):601-6.
Score: 0.119
-
Davids JS, Alavi K, Andres Cervera-Servin J, Choi CS, Sturrock PR, Sweeney WB, Maykel JA. Routine preoperative restaging CTs after neoadjuvant chemoradiation for locally advanced rectal cancer are low yield: a retrospective case study. Int J Surg. 2014 Dec; 12(12):1295-9.
Score: 0.106
-
Bordeianou L, Maguire LH, Alavi K, Sudan R, Wise PE, Kaiser AM. Sphincter-sparing surgery in patients with low-lying rectal cancer: techniques, oncologic outcomes, and functional results. J Gastrointest Surg. 2014 Jul; 18(7):1358-72.
Score: 0.103
-
Jordan KW, Nordenstam J, Lauwers GY, Rothenberger DA, Alavi K, Garwood M, Cheng LL. Metabolomic characterization of human rectal adenocarcinoma with intact tissue magnetic resonance spectroscopy. Dis Colon Rectum. 2009 Mar; 52(3):520-5.
Score: 0.072
-
Gaertner WB, Hagerman GF, Finne CO, Alavi K, Jessurun J, Rothenberger DA, Madoff RD. Fistula-associated anal adenocarcinoma: good results with aggressive therapy. Dis Colon Rectum. 2008 Jul; 51(7):1061-7.
Score: 0.067